Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US COVID-19 Vaccine Booster Plan Also Boosts Pressure On FDA

Executive Summary

The plan’s White House announcement was described as a transparency move, but meeting its 20 September target start date requires both the FDA and ACIP to act quickly on boosters.

You may also be interested in...



US FDA ‘Actively Working’ To Fill Vaccine Leadership Positions Ahead Of Next Round Of COVID Reviews

As decisions on additional boosters and childhood inoculations loom, CBER Director Peter Marks is still heading the vaccines division on an acting basis since the departures of Marion Gruber and Philip Krause last year. Who might succeed them?

Did The US FDA Mix Politics And Science With Its Cancer Guidance Announcement?

Three new guidances were announced the morning of President Biden’s State of the Union address, but experts said the move did not equate with past White House pressure on agency decisions.

Former Official Petitions US FDA To Stop Reviewing Russian Firms' Applications Amid Ukraine Invasion

Request from Tim Coté, former Office of Orphan Products Development director, could drag agency back into a political arena it's been trying to avoid. Coté, now consulting through Only Orphans Coté, filed a citizen petition asking agency to “completely freeze all administrative actions on any regulatory requests,” from drug and device companies headquartered in Russia or with majority Russian ownership.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel